Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
Pfizer is stuck on Triana’s molecular glue degraders
by Sarah Braner
October 20, 2024
| A version of this story appeared in
Volume 102, Issue 33
Pfizer has entered a partnership and licensing agreement with Triana Biomedicines to discover molecular glue degraders. The small molecules are meant to stick to a protein of interest, marking it for degradation by the body’s cell machinery. Triana focuses on glue degraders for cancer treatment. It will lead discovery efforts, while Pfizer will select promising molecules. Triana will get $49 million up front; it could also garner more than $1.5 billion in milestone payments.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X